A Phase 2 interventional study of Suzetrigine and Pregabalin in Diabetic Peripheral Neuropathy, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 50 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of VX-548 doses in treating Painful DPN.
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Diagnosis of diabetes mellitus type 1 or type 2 with
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Pregabalin 100 mg 3 times per day (tid) for 12 weeks
Drug: Pregabalin · Drug: Placebo (matched to SUZ)
Participants received SUZ 23 mg tablet once daily (qd) for 12 weeks.
Drug: Suzetrigine · Drug: Placebo (matched to pregabalin)
Participants received SUZ 46 mg tablet qd for 12 weeks.
Drug: Suzetrigine · Drug: Placebo (matched to pregabalin)
Participants received SUZ 69 mg tablet qd for 12 weeks.
Drug: Suzetrigine · Drug: Placebo (matched to pregabalin)
Tablets for oral administration.
Also known as: VX-548, SUZ
Capsules for oral administration.
Placebo matched to SUZ for oral administration.
Placebo matched to pregabalin for oral administration.
Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS)
Change from baseline in the weekly mean of the daily Numeric Pain Rating Scale (NPRS) score assessing average pain intensity in the last 24 hours. Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain.
Time frame: Baseline, At Week 12
Change From Baseline in the Weekly Average of the Daily Sleep Interference Scale (DSIS) Score
Change from baseline in the weekly mean of the Daily Sleep Interference Scale (DSIS) score, which asks participants to describe how pain interfered with the participant's sleep. Response options for the DSIS range from 0 (none) to 10 (severe).
Time frame: Baseline, At Week 12
Percentage of Participants With Greater Than or Equal to (≥) 30 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with ≥30% reduction from baseline in the weekly average NPRS score at Week 12 was reported.
Time frame: Baseline, At Week 12
Percentage of Participants With ≥50 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain.The percentage of participants with ≥50% reduction from baseline in the weekly average NPRS score at Week 12 was reported.
Time frame: Baseline, At Week 12
Percentage of Participants With ≥70 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with ≥70% reduction from baseline in the weekly average NPRS score at Week 12 was reported.
Time frame: Baseline, At Week 12
Percentage of Participants Categorized as "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Assessment
PGIC is an instrument that measures change in participants' overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: Baseline, At Week 12
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 14
| Milestone | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Started | 55 | 28 | 55 | 56 |
| Safety set | 54 | 28 | 55 | 55 |
| Modified full analysis set (mfas) | 49 | 24 | 50 | 50 |
| Completed | 46 | 24 | 46 | 47 |
| Not completed | 9 | 4 | 9 | 9 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal of consent (not due to ae) | 1 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Sponsor decision | 1 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 1 |
| Withdrew: Randomized but did not receive study drug | 1 | 0 | 0 | 1 |
| Withdrew: Enrolled at clinical trial site excluded from mfas due to lack of compliance with study drug | 5 | 4 | 5 | 5 |
Change from baseline in the weekly mean of the daily Numeric Pain Rating Scale (NPRS) score assessing average pain intensity in the last 24 hours. Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain.
| units on a scale | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) | -2.09 (-2.65 to -1.52) | -2.18 (-2.94 to -1.41) | -2.11 (-2.67 to -1.55) | -2.26 (-2.82 to -1.70) |
Change from baseline in the weekly mean of the Daily Sleep Interference Scale (DSIS) score, which asks participants to describe how pain interfered with the participant's sleep. Response options for the DSIS range from 0 (none) to 10 (severe).
| units on a scale | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Change From Baseline in the Weekly Average of the Daily Sleep Interference Scale (DSIS) Score | -2.42 (-3.02 to -1.83) | -2.20 (-3.00 to -1.41) | -2.44 (-3.01 to -1.87) | -2.15 (-2.74 to -1.55) |
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with ≥30% reduction from baseline in the weekly average NPRS score at Week 12 was reported.
| percentage of participants | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Percentage of Participants With Greater Than or Equal to (≥) 30 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS | 44.9 | 70.8 | 46.0 | 48.0 |
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain.The percentage of participants with ≥50% reduction from baseline in the weekly average NPRS score at Week 12 was reported.
| percentage of participants | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Percentage of Participants With ≥50 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS | 22.4 | 41.7 | 32.0 | 34.0 |
Pain intensity was recorded on 11-point NPRS, score range: 0 to 10, where 0= no pain and 10= worst imaginable pain. The percentage of participants with ≥70% reduction from baseline in the weekly average NPRS score at Week 12 was reported.
| percentage of participants | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Percentage of Participants With ≥70 Percent Reduction From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS | 10.2 | 8.3 | 22.0 | 22.0 |
PGIC is an instrument that measures change in participants' overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
| percentage of participants | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Percentage of Participants Categorized as "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Assessment | 46.9 | 50.0 | 52.0 | 50.0 |
| Participants | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Participants with TEAEs | 20 | 14 | 21 | 31 |
| Participants with SAEs | 1 | 0 | 2 | 1 |
Collected over Day 1 up to Week 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | 0/54 (0%) | 1/54 (1.9%) | 12/54 (22.2%) |
| Suzetrigine (SUZ): Low Dose | 0/28 (0%) | 0/28 (0%) | 4/28 (14.3%) |
| Suzetrigine (SUZ): Mid Dose | 1/55 (1.8%) | 2/55 (3.6%) | 5/55 (9.1%) |
| Suzetrigine (SUZ): High Dose | 0/55 (0%) | 1/55 (1.8%) | 7/55 (12.7%) |
| Event | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 1/54 | 0/28 | 0/55 | 0/55 |
| CellulitisInfections and infestations | 0/54 | 0/28 | 0/55 | 1/55 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/54 | 0/28 | 1/55 | 0/55 |
| ArteriosclerosisVascular disorders | 0/54 | 0/28 | 1/55 | 0/55 |
| Event | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose |
|---|---|---|---|---|
| Creatinine renal clearance decreasedInvestigations | 1/54 | 0/28 | 1/55 | 6/55 |
| Back painMusculoskeletal and connective tissue disorders | 0/54 | 3/28 | 0/55 | 0/55 |
| DizzinessNervous system disorders | 5/54 | 0/28 | 1/55 | 0/55 |
| Weight increasedInvestigations | 4/54 | 0/28 | 0/55 | 0/55 |
| Oedema peripheralGeneral disorders | 3/54 | 1/28 | 0/55 | 0/55 |
| HeadacheNervous system disorders | 2/54 | 0/28 | 3/55 | 1/55 |
Baseline data was analyzed based on the Modified Full Analysis Set (mFAS), defined as all randomized participants who have received at least 1 dose of study drug and are not from Site 115.
| Age, Continuous(years) | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose | Total |
|---|---|---|---|---|---|
| Mean | 63.0 ± 7.9 | 60.9 ± 6.6 | 61.7 ± 8.6 | 61.4 ± 8.8 | 61.9 ± 8.2 |
| Sex: Female, Male(Participants) | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose | Total |
|---|---|---|---|---|---|
| Female | 22 | 12 | 22 | 21 | 77 |
| Male | 27 | 12 | 28 | 29 | 96 |
| Race/Ethnicity, Customized(Participants) | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 2 | 9 | 4 | 22 |
| Not Hispanic or Latino | 42 | 22 | 41 | 46 | 151 |
| Race/Ethnicity, Customized(Participants) | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose | Total |
|---|---|---|---|---|---|
| White | 32 | 15 | 33 | 35 | 115 |
| Black or African American | 16 | 7 | 15 | 14 | 52 |
| Asian | 0 | 0 | 2 | 0 | 2 |
| American Indian or Alaska Native | 1 | 0 | 0 | 1 | 2 |
| Other | 0 | 1 | 0 | 0 | 1 |
| Multiracial | 0 | 1 | 0 | 0 | 1 |
| Baseline Weekly Average Pain Intensity as Recorded on Numeric Pain Rating Scale (NPRS)(units on a scale) | Pregabalin | Suzetrigine (SUZ): Low Dose | Suzetrigine (SUZ): Mid Dose | Suzetrigine (SUZ): High Dose | Total |
|---|---|---|---|---|---|
| Mean | 5.99 ± 1.27 | 5.70 ± 1.32 | 5.88 ± 0.97 | 5.83 ± 1.23 | 5.87 ± 1.18 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Dec 2022 to primary completion in Oct 2023, 9 months.
Results were first posted in Jul 2025, 1 year 8 months after primary completion. A results delay was requested in Oct 2024.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →